- Bioanalysis and DMPK Facility
Collaboration to provide expanded use of Paradigm Cancer Diagnostic (PCDx™) service by oncologists across large oncology network
SCOTTSDALE, AZ and ANN ARBOR, MI Monday, April 20, 2015 -- Paradigm and Translational Drug Development (TD2) today announced a partnership under which Paradigm will provide their PCDx test to TD2’s affiliated oncology provider networks.
PCDx is a Next-Generation Sequencing (NGS) based diagnostic test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a patients tumor’s DNA, RNA & Protein. The service is unique as the only commercially available NGS-based assay that interrogates DNA mutations, copy number variations, gene fusions and messenger RNA expression (mRNA) in typically less than five business days.
This collaboration with Paradigm will provide oncologists in the TD2 networks access to this cutting edge technology and make possible more informed and individually tailored treatment strategies for patients.
Click here for full press release.